ESMO Asia Congress | Conference

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

December 20th 2024

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

December 19th 2024

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

December 19th 2024

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

November 23rd 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the ​OPAL trial in EGFR-mutant non–small cell lung cancer.

Sotorasib Displays Disease Control, Safety in KRAS G12C–Mutant Gastrointestinal Cancers

November 22nd 2020

Sotorasib was well tolerated and led to disease control in the majority of patients with heavily pretreated KRAS G12C–mutant gastrointestinal malignancies.

Sugemalimab/Chemo Combo Elicits Clinically Meaningful PFS Benefit in Metastatic NSCLC

November 21st 2020

November 21, 2020 - The addition of sugemalimab to chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit in the frontline treatment of patients with metastatic non–small cell lung cancer versus placebo plus chemotherapy.

Dr. Price on the Safety, Efficacy of AMG 510 in Advanced Gastrointestinal Cancers

November 21st 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses the safety and efficacy of AMG 510 in patients with advanced gastrointestinal cancers.

Dr. Perol on EGFR TKI/Chemotherapy Combinations in Advanced EGFR+ NSCLC

November 21st 2020

Maurice Perol, MD, discusses combination regimens comprised of chemotherapy and EGFR TKIs in the treatment of patients with EGFR-mutated advanced non–small cell lung cancer, as investigated in the OPAL trial presented during the ESMO Asia Virtual Congress 2020.

Sintilimab/Bevacizumab Biosimilar Combo Shows Superior OS, PFS Over Sorafenib in Advanced Unresectable HCC

November 21st 2020

November 21, 2020 - Frontline sintilimab injection in combination with bevacizumab biosimilar injection resulted in a significant improvement in overall survival and progression-free survival per Independent Radiographic Review Committee versus sorafenib in patients with advanced unresectable hepatocellular carcinoma.

Maintenance Niraparib, Given at Individualized Starting Dose, Improves PFS in Chinese Patients With Ovarian Cancer

November 21st 2020

November 21, 2020 — Maintenance niraparib, when administered at an individualized starting dose, led to a 70% reduction in the risk of disease progression or death compared with placebo in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy.

Atezolizumab/Nab-Paclitaxel Induces Clinically Meaningful OS Benefit in PD-L1+ Locally Advanced or Metastatic TNBC

November 20th 2020

The combination of atezolizumab and nab-paclitaxel led to a clinically meaningful overall survival benefit in treatment-naïve patients with locally advanced or metastatic triple-negative breast cancer who had PD-L1 expressing tumor-infiltrating immune cells.

Asian Patients With HR+, HER2- Breast Cancer Have Higher Risk of Recurrence, May Benefit From Additional Adjuvant Abemaciclib

November 20th 2020

November 20, 2020 - Patients from Asian countries with hormone receptor–positive, HER2-negative breast cancer may have a higher risk of disease recurrence than those from non-Asian countries, suggesting that this population may benefit from additional adjuvant treatment with abemaciclib.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

November 20th 2020

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Osimertinib Plus Chemotherapy Is Well Tolerated in Frontline EGFR+ NSCLC

November 20th 2020

November 20, 2020 - Osimertinib in combination with platinum plus pemetrexed was well tolerated in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer.

Blood-Based Methylation Assay Enables Early, Accurate Detection of Solid Tumors

November 20th 2020

The noninvasive blood-based targeted methylation assay ELSA-seq identified early cancers with high specificity and provided accurate predictions of the tissue of origin.

Prognostic Identifiers for ES-SCLC Are Not Revealed in CASPIAN Subgroup Analysis

November 20th 2020

November 20, 2020 - Exploratory subgroup analysis of patients with extensive-stage small-cell lung cancer who derived a progression-free survival benefit with durvalumab plus platinum-based chemotherapy lasting longer than 12 months in the CASPIAN trial did not reveal any clinical characteristics that could serve as predictive factors for benefit with the monoclonal antibody.